The differential effects and distinct molecular pathways associated with AHR and ELAVL1 modulation highlight their potential as therapeutic targets for PDAC treatment, particularly in overcoming chemoresistance and inhibiting tumour progression. This evidence concerns the gene ELAVL1 and neoplasm.